Revelation Biosciences names Avance Clinical as CRO for Phase 2/3 Gemini AKI trial

• Revelation Biosciences selected Avance Clinical as contract research organization for its Phase 2/3 adaptive TITAN study of Gemini in acute kidney injury.
• Avance will run trial execution, including site operations, patient recruitment, safety oversight, data management, data quality, analysis.
• The company targets a study start later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260819546599) on August 19, 2026, and is solely responsible for the information contained therein.